SBP GROUP Shares Surge Over 5% in Early Trading on Deepened Strategic Alliance with GLAXOSMITHKLINE

Deep News07-09

Shares of SBP GROUP (01177) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million.

Expanding a Strategic Partnership

On July 8, SBP GROUP announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., is deepening its exclusive strategic collaboration with GlaxoSmithKline PLC (GSK), originally established in May 2026. This move aims to broaden access to two innovative respiratory drugs for more patients in China. This development represents a significant step forward in the strategic partnership between the group and GSK, marking an expansion of their collaborative focus from liver diseases into the respiratory disease sector.

Terms of the New Agreement

Under the terms of the agreement, the group has secured the commercial rights in mainland China for two of GSK's innovative respiratory medicines: fluticasone furoate/umeclidinium/vilanterol (brand name: Trelegy Ellipta) and umeclidinium/vilanterol (brand name: Anoro Ellipta). SBP GROUP will be responsible for the importation, distribution, hospital access, and promotional activities related to these products in mainland China. All sales revenue generated from these products will be recognized as revenue for the Zhengda Tianqing subsidiary.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115056703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115056703","market":"hk","top_or_hot":-1,"title":"SBP GROUP Shares Surge Over 5% in Early Trading on Deepened Strategic Alliance with GLAXOSMITHKLINE","media":"Deep News","content":"<p>Shares of <b>SBP GROUP</b> (<b>01177</b>) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million.<br><br>\n<b>Expanding a Strategic Partnership</b><br><br>\nOn July 8, SBP GROUP announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., is deepening its exclusive strategic collaboration with <b>GlaxoSmithKline PLC</b> (<b>GSK</b>), originally established in May 2026. This move aims to broaden access to two innovative respiratory drugs for more patients in China. This development represents a significant step forward in the strategic partnership between the group and GSK, marking an expansion of their collaborative focus from liver diseases into the respiratory disease sector.<br><br>\n<b>Terms of the New Agreement</b><br><br>\nUnder the terms of the agreement, the group has secured the commercial rights in mainland China for two of GSK's innovative respiratory medicines: fluticasone furoate/umeclidinium/vilanterol (brand name: Trelegy Ellipta) and umeclidinium/vilanterol (brand name: Anoro Ellipta). SBP GROUP will be responsible for the importation, distribution, hospital access, and promotional activities related to these products in mainland China. All sales revenue generated from these products will be recognized as revenue for the Zhengda Tianqing subsidiary.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SBP GROUP Shares Surge Over 5% in Early Trading on Deepened Strategic Alliance with GLAXOSMITHKLINE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSBP GROUP Shares Surge Over 5% in Early Trading on Deepened Strategic Alliance with GLAXOSMITHKLINE\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-09 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>SBP GROUP</b> (<b>01177</b>) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million.<br><br>\n<b>Expanding a Strategic Partnership</b><br><br>\nOn July 8, SBP GROUP announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., is deepening its exclusive strategic collaboration with <b>GlaxoSmithKline PLC</b> (<b>GSK</b>), originally established in May 2026. This move aims to broaden access to two innovative respiratory drugs for more patients in China. This development represents a significant step forward in the strategic partnership between the group and GSK, marking an expansion of their collaborative focus from liver diseases into the respiratory disease sector.<br><br>\n<b>Terms of the New Agreement</b><br><br>\nUnder the terms of the agreement, the group has secured the commercial rights in mainland China for two of GSK's innovative respiratory medicines: fluticasone furoate/umeclidinium/vilanterol (brand name: Trelegy Ellipta) and umeclidinium/vilanterol (brand name: Anoro Ellipta). SBP GROUP will be responsible for the importation, distribution, hospital access, and promotional activities related to these products in mainland China. All sales revenue generated from these products will be recognized as revenue for the Zhengda Tianqing subsidiary.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YS42.EUR","symbol_name":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","start_time":0,"source_url":"","article_id":"1115056703","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115056703","pubTimestamp":1783563660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of SBP GROUP (01177) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million. Expanding a Strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK4007":"制药","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","GSK":"葛兰素史克","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1589":"北水核心资产","GSK.UK":"葛兰素史克","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","01177":"中国生物制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","GSKH":"GSK plc ADRhedged","BK4532":"文艺复兴科技持仓"},"translate_title":"与葛兰素史克深化战略联盟，SBP集团股价早盘飙升逾5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":1,"GSK":1,"01177":1,"GSK.UK":1},"content_text":"Shares of SBP GROUP (01177) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million.\nExpanding a Strategic Partnership\nOn July 8, SBP GROUP announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., is deepening its exclusive strategic collaboration with GlaxoSmithKline PLC (GSK), originally established in May 2026. This move aims to broaden access to two innovative respiratory drugs for more patients in China. This development represents a significant step forward in the strategic partnership between the group and GSK, marking an expansion of their collaborative focus from liver diseases into the respiratory disease sector.\nTerms of the New Agreement\nUnder the terms of the agreement, the group has secured the commercial rights in mainland China for two of GSK's innovative respiratory medicines: fluticasone furoate/umeclidinium/vilanterol (brand name: Trelegy Ellipta) and umeclidinium/vilanterol (brand name: Anoro Ellipta). SBP GROUP will be responsible for the importation, distribution, hospital access, and promotional activities related to these products in mainland China. All sales revenue generated from these products will be recognized as revenue for the Zhengda Tianqing subsidiary.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115056703","isCrawlerRequest":true}